Short answer
Editas Medicine, Inc. (EDIT) filed its Q3 2025 10-Q quarterly report on Nov 10, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $8M (up 12265.6% year over year) with net income of −$25M.
Q3 2025 key financials · XBRL
- Revenue
- $8M
- +12265.6% YoY · +110.8% QoQ
- Net income
- −$25M
- +59.6% YoY · +52.8% QoQ
- Operating margin
- -325.4%
- EPS (diluted)
- −$0.26
- +65.3% YoY · +58.1% QoQ
Source: XBRL data from the Editas Medicine, Inc. (EDIT) Q3 2025 10-Q on SEC EDGAR. USD.
Editas Medicine, Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $7.5M vs $0.1M YoY, driven by BMS milestone recognition
- Net loss $25.1M vs $62.1M YoY, a 60% reduction
- Operating expenses $32.1M, down 51% from $65.7M YoY
- R&D expense $19.8M, down 58% after reni-cel discontinuation and workforce reduction
- EDIT-401 IND or CTA submission targeted by mid-2026, human proof-of-concept targeted by year-end 2026
Risk Factors
- Patent priority risk: CAFC remand on May 12, 2025 reopened Broad–CVC interference proceedings
- Regulatory and legal risk: PTAB’s eventual decision could narrow or invalidate in-licensed CRISPR/Cas9 claims
- Competitive risk: Loss of European patents could enable third parties to commercialize similar gene-editing technologies
- Operational risk: Five parallel PTAB interferences create uncertain timelines and management distraction
- Intellectual-property concentration: Broad in-licensed patents underpin rights to CRISPR/Cas9 technology
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Editas Medicine, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.